In:
Cancer, Wiley, Vol. 126, No. 12 ( 2020-06-15), p. 2821-2828
Abstract:
This phase 2, double‐blinded, placebo‐controlled trial in patients with recurrent glioblastoma (rGBM) through NRG oncology shows that the combination of bevacizumab plus trebananib—an angiopoietin (Ang) inhibitor—does not significantly improve 6‐month progression‐free survival (PFS) rate, PFS, or overall survival for patients with rGBM compared with bevacizumab plus placebo. The Ang1 blocking effects of trebananib may somehow counteract or negate the antitumor effects of the Ang2–vascular endothelial growth factor blockade.
Type of Medium:
Online Resource
ISSN:
0008-543X
,
1097-0142
Language:
English
Publisher:
Wiley
Publication Date:
2020
detail.hit.zdb_id:
1479932-7
detail.hit.zdb_id:
2599218-1
detail.hit.zdb_id:
2594979-2
detail.hit.zdb_id:
1429-1
Permalink